TENX Tenax Therapeutics Inc

P/E --
Forward P/E 0.299
Price/Sales 414.72
Beta 0.917
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 Tenax Therapeutics is trading 6.2% up in after-hours trading with no clear catalyst confirmed

Tenax Therapeutics is trading 6.2% higher at $1.44, with no verified October 16 announcement explaining the after-hours rebound. - It closed at $1.36 on...

🔴 Tenax Therapeutics is trading 6.3% down today amid biotech weakness

Tenax Therapeutics is trading at $1.42, down 6.29%, amid biotech and broader-market weakness. - The XBI is down 2.06%. - No new company-specific announcement...

Tenax Therapeutics Sees Sphera Boost Stake 33.6%

Tenax Therapeutics Sees Sphera Boost Stake 33.6%

Reports dated October 15, 2026, said Sphera Funds Management Ltd. increased its investment in Tenax Therapeutics. Sphera acquired an additional 669,800 shares...

🔴 Tenax Therapeutics is trading 7.2% down today with no clear new company-specific catalyst

Tenax Therapeutics is trading at $1.70, down 7.21%, with no clear new company-specific catalyst identified for October 13. • XBI fell 2.01% during the regular...

Tenax Therapeutics Pauses Enrollment to Amend Phase 3 LEVEL-2 Trial Protocol

Tenax Therapeutics Pauses Enrollment to Amend Phase 3 LEVEL-2 Trial Protocol

Tenax Therapeutics has temporarily paused enrollment in its Phase 3 LEVEL-2 clinical trial for its drug candidate TNX-103 (levosimendan) in patients with...

🟢 Tenax Therapeutics is trading 5% up today as XBI gains 2.55%

Tenax Therapeutics is trading at $1.95, up 5.01% amid biotech-sector strength, with XBI up 2.55% and outperforming the broader market on September 18, 2026. -...

Tenax Therapeutics Insiders Buy Shares, Signaling Confidence After Trial Setback

Tenax Therapeutics Insiders Buy Shares, Signaling Confidence After Trial Setback

Tenax Therapeutics CEO Christopher Giordano and CFO Thomas R. Staab II purchased company stock in open-market transactions. Giordano acquired 10,850 shares on...

🔴 Tenax Therapeutics is trading 5% down today amid broader risk-off trading

Tenax Therapeutics is trading 5% down at $2.02, with the decline appearing primarily linked to broader risk-off trading. - Shares rose 7.58% to $2.13 on...

ADAR1 Keeps Buying as Tenax Pitches a Comeback Story — But Can a Failed Trial Really Be Reframed Into a Win?

ADAR1 Keeps Buying as Tenax Pitches a Comeback Story — But Can a Failed Trial Really Be Reframed Into a Win?

Shares of Tenax Therapeutics jumped +7.6% to $2.13 on a broadly weaker market day as two catalysts converged: CEO Chris Giordano took the stage at the 12th...

🟢 Tenax Therapeutics is trading 11.36% up today following updated Phase 3 LEVEL trial results at Cantor conference

Tenax Therapeutics is trading 11.36% up at $2.21 as investor interest increased following its September 9, 2026 presentation at the Cantor Global Healthcare...

🟢 Tenax Therapeutics is trading 7.6% up today ahead of its September 9 conference presentation

Tenax Therapeutics is trading at $2.13, up +7.58%, on renewed investor interest ahead of its September 9, 2026 Cantor Global Healthcare Conference...

Tenax Therapeutics Stake Hits 15%, Signaling Confidence Ahead of Conference

Tenax Therapeutics Stake Hits 15%, Signaling Confidence Ahead of Conference

ADAR1 Capital Management, LLC significantly increased its ownership stake in Tenax Therapeutics, Inc. (NASDAQ:TENX). The firm purchased 770,333 shares on...

🟢 Tenax Therapeutics is trading 5.05% up in pre-market ahead of Cantor Global Healthcare Conference

Tenax Therapeutics is trading at $2.08 (+5.05%) in pre-market; investor interest may be supported by its scheduled presentation, though no verified September...

🟢 Tenax Therapeutics is trading 5.56% up in after-hours trading; catalyst unconfirmed

Tenax Therapeutics is trading at $2.09, up 5.56%, with no verified September 8 company announcement directly explaining the after-hours move. - Closed at...

FMR Takes 1.4% Stake in Tenax Therapeutics, Backing Phase 3 Pharma Developer

FMR Takes 1.4% Stake in Tenax Therapeutics, Backing Phase 3 Pharma Developer

FMR LLC disclosed a 1.4% ownership stake in Tenax Therapeutics Inc. through a recent SEC Schedule 13G/A filing. Tenax Therapeutics is a development-stage...

🟢 Tenax Therapeutics is trading 10.57% up today — no clear company-specific catalyst

Tenax Therapeutics is trading at $2.15, 10.57% up on September 8, 2026, with no clear company-specific announcement explaining the move. - Scheduled to...

🟢 Tenax Therapeutics is trading 5.4% up today; no company-specific announcement explains move

Tenax Therapeutics is trading 5.4% up at $2.04, based on live price context; no September 8, 2026 company-specific announcement explicitly explains the...

🟢 Tenax Therapeutics is trading 5.1% up today

Tenax Therapeutics is trading 5.1% up at $1.87, with no clear company-specific catalyst identified for the move. - The latest company announcement was a...

🟢 Tenax Therapeutics is trading 6.76% up today as XBI gains 2.75%

Tenax Therapeutics is trading $1.98 (+6.76%), with the advance appearing sector-driven rather than linked to a fresh company catalyst. - No new...

🟢 Tenax Therapeutics is trading 6% up today in pre-market

Tenax Therapeutics is trading at $1.96, up 5.95%, after closing at $1.85 on September 2, 2026, with no clear catalyst identified. - No new company-specific...